ClinicalTrials.gg
Not yet recruitingNCT07868263Updated Oct 9, 2026

Video-Assisted Core Stabilization Exercises in Children With Developmental Coordination Disorder

An interventional study of Video-Assisted Fun-Core Exercise Program and Home-Based Core Stabilization Exercise Program in Developmental Coordination Disorder (DCD), sponsored by Istanbul University. Not yet recruiting. Open to participants aged 5 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Istanbul University · Not applicable, Interventional, and Treatment

Updated Oct 9, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
5 Years to 14 Years
Sex
All
01

Study summary

This single-center, single-blind, prospective randomized controlled trial aims to investigate the effects of a video-assisted core stabilization exercise program (Fun-Core) on motor competence, balance, and gait in children with DCD. Children who meet the eligibility criteria will be randomly assigned to either the intervention group or the control group. The intervention group will participate in a video-assisted, story-based, child-friendly Fun-Core exercise program delivered through a web-based platform, whereas the control group will receive the same core stabilization exercises as a home-based program provided in an illustrated brochure format. In both groups, the intervention will last 8 weeks, with exercises performed 3 days per week for approximately 30 minutes per session. The exercise program will consist of two progressive levels, with Level 1 performed during weeks 1-4 and Level 2 during weeks 5-8. Progression to Level 2 will depend on correct and pain-free performance of the exercises, completion of at least 75% of the planned sessions, and absence of exercise-related adverse events.

The primary outcome will be motor competence, assessed using the Movement Assessment Battery for Children-Third Edition (MABC-3). The MABC-3 evaluates motor performance across three domains: Manual Dexterity, Aiming and Catching, and Balance. Raw performance scores are converted into age-adjusted standard scores and percentile ranks, with higher scores indicating better motor performance.

Secondary outcomes will include balance, functional mobility, participation, health-related quality of life, and static and dynamic pedobarographic parameters. Balance will be evaluated using the Pediatric Balance Scale (PBS), a 14-item scale scored from 0 to 56, with higher scores representing better balance performance. Functional mobility will be evaluated using the Modified Timed Up and Go Test (M-TUG) by recording the time required to stand from a chair, complete the specified mobility task, return, and sit down; shorter completion times indicate better functional mobility. Participation and environmental factors will be evaluated using the Participation and Environment Measure for Children and Youth (PEM-CY), a parent-reported measure assessing participation across home, school, and community settings. Health-related quality of life will be assessed using the Pediatric Quality of Life Inventory 4.0 (PedsQL 4.0), including physical, emotional, social, and school functioning domains, using child self-report and parent proxy-report forms. Scores are transformed to a 0-100 scale, with higher scores indicating better health-related quality of life.

Gait and plantar loading characteristics will additionally be evaluated using static and dynamic pedobarographic assessment with a pressure platform integrated with FreeStep 2.0 software. Static assessment will include plantar pressure distribution, right-to-left load distribution, forefoot-to-rearfoot load distribution, and center of pressure (CoP) parameters. Dynamic assessment during walking at a self-selected natural speed will include plantar pressure distribution, maximum plantar pressure, load transfer patterns, and gait-line parameters.

All outcome assessments will be performed by an investigator blinded to group allocation at baseline (Week 0), immediately after the 8-week intervention (Week 8). During the intervention period, participants will be contacted weekly to monitor exercise adherence, general health status, and possible adverse events.

Eligible participants will be children aged 5-14 years who meet the DSM-5 diagnostic criteria for DCD and have an MABC-3 Total Standard Score corresponding to the 16th percentile or below. Exclusion criteria will include treatment for motor problems within the previous 6 months; a neurological disorder that primarily explains the motor difficulties; intellectual disability that substantially interferes with participation in assessments or exercises; moderate-to-severe autism spectrum disorder or attention-deficit/hyperactivity disorder, or behavioral problems that interfere with participation; orthopedic deformities preventing exercise; previous lumbar or lower-extremity surgery; moderate-to-severe visual or hearing impairment; and epilepsy or another uncontrolled neurological condition.

02

Conditions studied

  • Developmental Coordination Disorder (DCD)

Browse trials for

Keywords

  • Developmental Coordination Disorder (DCD)
  • Core Stabilization Exercise
  • Video-Assisted Exercise
  • Motor Competence
  • Balance and Gait
03

In context

Motor Skills Disorders

98 studies on the registry are indexed under Motor Skills Disorders; 26 are open to participants now.

This study's planned enrollment of 22 is below the median of 40 across 71 interventional studies indexed under Motor Skills Disorders.

Browse Motor Skills Disorders studies →

Lead sponsor

Istanbul University is the lead sponsor of 507 studies on the registry; 80 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 5-14 years. Diagnosis of Developmental Coordination Disorder (DCD) according to the DSM-5 diagnostic criteria.

Movement Assessment Battery for Children-Third Edition (MABC-3) Total Standard Score at or below the 16th percentile.

Exclusion criteria

Exclusion Criteria:

  • Having received any treatment for motor problems within the previous 6 months. Presence of any neurological disorder that could primarily explain the motor difficulties.

Presence of intellectual disability at a level that would significantly interfere with the ability to participate in the assessments or exercise program.

Presence of moderate-to-severe Autism Spectrum Disorder (ASD) or Attention-Deficit/Hyperactivity Disorder (ADHD), or behavioral problems severe enough to interfere with participation in the assessments or exercise program.

Presence of an orthopedic deformity that may prevent participation in the exercise program.

History of lumbar spine or lower-extremity surgery. Moderate-to-severe visual or hearing impairment. Epilepsy or any uncontrolled neurological condition.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Video-Assisted Fun-Core Exercise Group

    Behavioral: Video-Assisted Fun-Core Exercise Program

  • Active comparator
    Home-Based Core Stabilization Exercise Group

    Behavioral: Home-Based Core Stabilization Exercise Program

Interventions

  • BehavioralVideo-Assisted Fun-Core Exercise Program

    An 8-week progressive core stabilization exercise program delivered through a web-based platform using video-assisted, story-based exercise content. Exercises will be performed three times per week for approximately 30 minutes per session.

  • BehavioralHome-Based Core Stabilization Exercise Program

    An 8-week progressive home-based core stabilization exercise program provided in an illustrated brochure format. Exercises will be performed three times per week for approximately 30 minutes per session.

06

What researchers measure

Primary outcomes

  1. Movement Assessment Battery for Children-Third Edition (MABC-3)

    The Movement Assessment Battery for Children-Third Edition (MABC-3) will be used to assess overall motor competence. The MABC-3 consists of eight motor tasks across three domains: Manual Dexterity, Aiming and Catching, and Balance. Raw scores are converted into age-adjusted standard scores using normative data. The MABC-3 Total Motor Score will be used as the primary outcome measure, with higher scores indicating better overall motor performance.

    Time frame: From baseline to 8 weeks (end of intervention)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.

Of 44 non-industry interventional studies with no phase under Motor Skills Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 39. This study's planned 2 months is below that.

Counting every sponsor, half of 44 studies reached it within 17 months; a quarter within 6 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2026
First posted
Oct 9, 2026
StartEst.
Oct 10, 2026
Primary completionEst.
Dec 10, 2026
CompletionEst.
Dec 14, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07868263
Responsible party
Şeyda Akbal (research assistant, Istanbul University) — Principal investigator
First posted
Oct 9, 2026
Start date
Oct 10, 2026 (estimated)
Primary completion
Dec 10, 2026 (estimated)
Completion
Dec 14, 2026 (estimated)
Last update
Oct 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion